ECSP13012372A - Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. - Google Patents

Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.

Info

Publication number
ECSP13012372A
ECSP13012372A ECSP13012372A ECSP13012372A EC SP13012372 A ECSP13012372 A EC SP13012372A EC SP13012372 A ECSP13012372 A EC SP13012372A EC SP13012372 A ECSP13012372 A EC SP13012372A
Authority
EC
Ecuador
Prior art keywords
diazepanos
pde
inhibitors
new derivatives
derivatives
Prior art date
Application number
Other languages
English (en)
Inventor
Armenta María Elena García
Ochoa Víctor Guillermo Álvarez
Morales Roberto Carlos Osnaya
Barajas Erika Alejandra Zarate
Original Assignee
World Trade Imp Exp Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Exp Wtie Ag filed Critical World Trade Imp Exp Wtie Ag
Publication of ECSP13012372A publication Critical patent/ECSP13012372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un compuesto de formula general I, procedimientos para su preparación, composiciones farmacéuticas que los contienen y el uso de éstos en el tratamiento de la disfunción eréctil.
ECSP13012372 2010-06-07 2013-01-07 Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. ECSP13012372A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010006227A MX2010006227A (es) 2010-06-07 2010-06-07 Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.

Publications (1)

Publication Number Publication Date
ECSP13012372A true ECSP13012372A (es) 2013-02-28

Family

ID=45097594

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012372 ECSP13012372A (es) 2010-06-07 2013-01-07 Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.

Country Status (7)

Country Link
EP (1) EP2578588A4 (es)
AR (1) AR081650A1 (es)
BR (1) BR112012031289A2 (es)
CO (1) CO6660496A2 (es)
EC (1) ECSP13012372A (es)
MX (1) MX2010006227A (es)
WO (1) WO2011154798A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
EP3887376A1 (en) * 2018-11-28 2021-10-06 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
ES2203078T3 (es) 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
ES2205945T3 (es) * 1998-10-23 2004-05-01 Pfizer Inc. Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales.
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
EP1002798A1 (en) 1998-11-20 2000-05-24 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative
WO2001003644A2 (en) 1999-07-09 2001-01-18 The Picower Institute For Medical Research Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction
EP1077214A1 (en) 1999-08-16 2001-02-21 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a pyrazolopyrimidinone derivative
WO2001019827A1 (en) 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
MXPA99010322A (es) 1999-11-10 2003-07-15 Europharm S A De C V Proceso para la preparacion de sildenafil.
YU93902A (sh) 2000-06-22 2005-11-28 Pfizer Products Inc. Postupak za pripremanje pirazolopirimidinona
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
EA201070056A1 (ru) 2007-06-26 2010-06-30 Солвей Фармасьютикалс Б.В. N-оксид силденафила в качестве пролекарства

Also Published As

Publication number Publication date
WO2011154798A1 (es) 2011-12-15
BR112012031289A2 (pt) 2016-11-01
MX2010006227A (es) 2011-12-14
EP2578588A1 (en) 2013-04-10
AR081650A1 (es) 2012-10-10
CO6660496A2 (es) 2013-04-30
EP2578588A4 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
CO6541643A2 (es) Derivados de imidazopirina como inhibidores de jak
SV2010003713A (es) Pirimidin-5-carboxamidas sustituidas 281
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
SV2010003767A (es) Compuestos pirazolicos 436
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
ECSP12012338A (es) Triazolopiridinas sustituidas
UY35275A (es) Derivados de aminopirazina
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.